China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) Stock Competitors & Peer Comparison
See 3320.HK's competitors and their performance on the HKSE and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 3320.HK and its HKSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 3320.HK | HK$4.57 | -0.87% | 28.7B | 6.10 | HK$0.75 | +4.77% |
| 6618.HK | HK$36.68 | -0.16% | 117.8B | 16.09 | HK$2.28 | N/A |
| 1177.HK | HK$5.60 | -0.62% | 99.7B | 16.80 | HK$0.33 | +2.14% |
| 0874.HK | HK$14.06 | -0.35% | 34.9B | 7.89 | HK$1.78 | +5.60% |
| 2096.HK | HK$11.30 | -1.82% | 29B | 14.91 | HK$0.76 | +1.83% |
| 0512.HK | HK$5.24 | -0.38% | 18.3B | 17.58 | HK$0.30 | +3.23% |
| 0719.HK | HK$5.71 | -0.17% | 8.6B | 12.89 | HK$0.44 | +3.02% |
| 2005.HK | HK$2.70 | +0.56% | 7.8B | 15.43 | HK$0.17 | +2.97% |
| 3613.HK | HK$6.50 | -0.31% | 5.4B | 8.02 | HK$0.81 | +6.15% |
| 1345.HK | HK$2.24 | +4.19% | 2.6B | 16.10 | HK$0.14 | +5.27% |
Stock Comparison
JD Health International Inc. (HKSE: 6618.HK)
3320.HK vs 6618.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 6618.HK has a market cap of 117.8B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 6618.HK trades at HK$36.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 6618.HK's P/E ratio is 16.09. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 6618.HK's ROE of +0.10%. Regarding short-term risk, 3320.HK is less volatile compared to 6618.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 6618.HK's competition here
Sino Biopharmaceutical Limited (HKSE: 1177.HK)
3320.HK vs 1177.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 1177.HK has a market cap of 99.7B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 1177.HK trades at HK$5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 1177.HK's P/E ratio is 16.80. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 1177.HK's ROE of +0.07%. Regarding short-term risk, 3320.HK is less volatile compared to 1177.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 1177.HK's competition here
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKSE: 0874.HK)
3320.HK vs 0874.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 0874.HK has a market cap of 34.9B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 0874.HK trades at HK$14.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 0874.HK's P/E ratio is 7.89. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 0874.HK's ROE of +0.07%. Regarding short-term risk, 3320.HK is more volatile compared to 0874.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 0874.HK's competition here
Simcere Pharmaceutical Group Limited (HKSE: 2096.HK)
3320.HK vs 2096.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 2096.HK has a market cap of 29B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 2096.HK trades at HK$11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 2096.HK's P/E ratio is 14.91. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 2096.HK's ROE of +0.17%. Regarding short-term risk, 3320.HK is less volatile compared to 2096.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 2096.HK's competition here
Grand Pharmaceutical Group Limited (HKSE: 0512.HK)
3320.HK vs 0512.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 0512.HK has a market cap of 18.3B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 0512.HK trades at HK$5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 0512.HK's P/E ratio is 17.58. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 0512.HK's ROE of +0.07%. Regarding short-term risk, 3320.HK is less volatile compared to 0512.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 0512.HK's competition here
Shandong Xinhua Pharmaceutical Company Limited (HKSE: 0719.HK)
3320.HK vs 0719.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 0719.HK has a market cap of 8.6B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 0719.HK trades at HK$5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 0719.HK's P/E ratio is 12.89. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 0719.HK's ROE of +0.04%. Regarding short-term risk, 3320.HK is more volatile compared to 0719.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 0719.HK's competition here
SSY Group Limited (HKSE: 2005.HK)
3320.HK vs 2005.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 2005.HK has a market cap of 7.8B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 2005.HK trades at HK$2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 2005.HK's P/E ratio is 15.43. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 2005.HK's ROE of +0.07%. Regarding short-term risk, 3320.HK is less volatile compared to 2005.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 2005.HK's competition here
Beijing Tong Ren Tang Chinese Medicine Company Limited (HKSE: 3613.HK)
3320.HK vs 3613.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 3613.HK has a market cap of 5.4B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 3613.HK trades at HK$6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 3613.HK's P/E ratio is 8.02. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 3613.HK's ROE of +0.10%. Regarding short-term risk, 3320.HK is more volatile compared to 3613.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 3613.HK's competition here
Shanghai Pioneer Holding Ltd (HKSE: 1345.HK)
3320.HK vs 1345.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 1345.HK has a market cap of 2.6B. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 1345.HK trades at HK$2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 1345.HK's P/E ratio is 16.10. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 1345.HK's ROE of +0.11%. Regarding short-term risk, 3320.HK is more volatile compared to 1345.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 1345.HK's competition here
Fangzhou Inc. (HKSE: 6086.HK)
3320.HK vs 6086.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 6086.HK has a market cap of 956M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 6086.HK trades at HK$0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 6086.HK's P/E ratio is -1232.14. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 6086.HK's ROE of +0.08%. Regarding short-term risk, 3320.HK is less volatile compared to 6086.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 6086.HK's competition here
Lee's Pharmaceutical Holdings Limited (HKSE: 0950.HK)
3320.HK vs 0950.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 0950.HK has a market cap of 789M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 0950.HK trades at HK$1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 0950.HK's P/E ratio is 10.30. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 0950.HK's ROE of +0.05%. Regarding short-term risk, 3320.HK is less volatile compared to 0950.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 0950.HK's competition here
Modern Chinese Medicine Group Co., Ltd. (HKSE: 1643.HK)
3320.HK vs 1643.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 1643.HK has a market cap of 594M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 1643.HK trades at HK$0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 1643.HK's P/E ratio is -41.25. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 1643.HK's ROE of -0.03%. Regarding short-term risk, 3320.HK is less volatile compared to 1643.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 1643.HK's competition here
Regent Pacific Group Limited (HKSE: 0575.HK)
3320.HK vs 0575.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 0575.HK has a market cap of 249.5M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 0575.HK trades at HK$0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 0575.HK's P/E ratio is -5.59. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 0575.HK's ROE of +0.31%. Regarding short-term risk, 3320.HK is more volatile compared to 0575.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 0575.HK's competition here
Tycoon Group Holdings Limited (HKSE: 3390.HK)
3320.HK vs 3390.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 3390.HK has a market cap of 232.4M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 3390.HK trades at HK$0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 3390.HK's P/E ratio is 62.50. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 3390.HK's ROE of +0.03%. Regarding short-term risk, 3320.HK is less volatile compared to 3390.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 3390.HK's competition here
Nanjing Sinolife United Company Limited (HKSE: 3332.HK)
3320.HK vs 3332.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 3332.HK has a market cap of 130.6M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 3332.HK trades at HK$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 3332.HK's P/E ratio is 3.52. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 3332.HK's ROE of +0.05%. Regarding short-term risk, 3320.HK is more volatile compared to 3332.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 3332.HK's competition here
China Health Group Inc. (HKSE: 8225.HK)
3320.HK vs 8225.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 8225.HK has a market cap of 79.6M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 8225.HK trades at HK$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 8225.HK's P/E ratio is -5.04. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 8225.HK's ROE of -0.22%. Regarding short-term risk, 3320.HK is more volatile compared to 8225.HK. This indicates higher risk in terms of short-term price fluctuations for 3320.HK.Check 8225.HK's competition here
Universal Health International Group Holding Limited (HKSE: 2211.HK)
3320.HK vs 2211.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 2211.HK has a market cap of 55.9M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 2211.HK trades at HK$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 2211.HK's P/E ratio is 26.72. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 2211.HK's ROE of -0.07%. Regarding short-term risk, 3320.HK is less volatile compared to 2211.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 2211.HK's competition here
New Ray Medicine International Holding Ltd. (HKSE: 6108.HK)
3320.HK vs 6108.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 6108.HK has a market cap of 47.1M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 6108.HK trades at HK$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 6108.HK's P/E ratio is -1.96. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 6108.HK's ROE of N/A. Regarding short-term risk, 3320.HK is less volatile compared to 6108.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 6108.HK's competition here
Pa Shun International Holdings Limited (HKSE: 0574.HK)
3320.HK vs 0574.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 0574.HK has a market cap of 39.8M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 0574.HK trades at HK$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 0574.HK's P/E ratio is -0.42. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 0574.HK's ROE of +0.11%. Regarding short-term risk, 3320.HK is less volatile compared to 0574.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 0574.HK's competition here
Sanai Health Industry Group Company Limited (HKSE: 1889.HK)
3320.HK vs 1889.HK Comparison August 2026
China Resources Pharmaceutical Group Ltd. (HKSE: 3320.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3320.HK stands at 28.7B. In comparison, 1889.HK has a market cap of 25.5M. Regarding current trading prices, 3320.HK is priced at HK$4.57 on the HKSE, while 1889.HK trades at HK$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3320.HK currently has a P/E ratio of 6.10, whereas 1889.HK's P/E ratio is -0.98. In terms of profitability, 3320.HK's ROE is +0.08%, compared to 1889.HK's ROE of N/A. Regarding short-term risk, 3320.HK is less volatile compared to 1889.HK. This indicates lower risk in terms of short-term price fluctuations for 3320.HK.Check 1889.HK's competition here